adults: a cross-sectional survey based on NHANES Yuanze Du, Wenxue Sun, Jiaqi Zhang, Jinfeng Wang, Kai Deng, Xiaowei Qiao, Jie Zhang, Xiaofang Zhang, Yueyuan Li, Xinyu Zhang, Xin Yang, Fangyu Cheng, Zongshuai Wang, Chunping Wang BMC Cardiovascular Disorders.2026;[Epub] CrossRef Integrated discovery of SBLR876: a potent RAGE inhibitor mitigating AGERAGENF-B-mediated cytotoxicity and inflammation in diabetic kidney disease Mesfer Mohammad AL Shahrani, Mohammad Abohassan, Ayed A
This happens because your body is adjusting to a higher amount of medication, and symptoms often improve with time
The approval matters because it validates a long-sought oral small-molecule route to GLP-1 agonism, with potentially major consequences for convenience, manufacturing scale, pricing, and patent strategy
It is unclear whether it exhibits cardioprotective effects in patients with post-PCI, AMI, or other cardiomyopathies
Available online at: (accessed May, 2026) 35 WangW.VolkowN